214 |
Optimal Antithrombotic Therapy and Ongoing Clinical Trials |
Duk-Woo Park |
Aug. 07. 18 |
213 |
TAVR for Bicuspid Valve: Clinical Outcome and Technical Considerations |
Jung-Min Ahn |
Aug. 07. 18 |
212 |
TAVR in Low Risk Patients |
Alan C. Yeung |
Aug. 07. 18 |
211 |
Low Gradient AS: How to Identify and Manage? |
Yong-Jin Kim |
Aug. 07. 18 |
210 |
Management of Asymptomatic Severe AS |
Duk-Hyun Kang |
Aug. 07. 18 |
209 |
ViV TAVR: The Role of Bioprosthetic Valve Fracture |
David Joel Cohen |
Aug. 07. 18 |
208 |
Sapien 3 or Evolut R: Different Indications? |
Alan C. Yeung |
Aug. 07. 18 |
207 |
CT Algorithm to Avoid Permanent Pacemaker and Para-Valvular Leakage |
Do-Yoon Kang |
Aug. 07. 18 |
206 |
Conscious Sedation or General Anesthesia for TAVR: When Should We Consider General Anesthesia? |
Kyoung Woon Joung |
Aug. 07. 18 |
205 |
Mainstream of TAVR: Minimalist Approach |
Duk-Woo Park |
Aug. 07. 18 |